[
    {
        "pregunta": "1. What are the key recommendations for perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty according to the 2022 American College of Rheumatology guideline?",
        "respuesta": "The 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) guideline for the perioperative management of antirheumatic medication in patients undergoing elective total hip or total knee arthroplasty emphasizes prioritizing medication management to decrease infection risk. However, specific details about the key recommendations regarding medication management and timing are not available from the provided information. The guideline suggests a shared decision-making process, considering that while the majority of informed patients may choose a recommended course of action, an appreciable minority may not.",
        "contexto": [
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable",
            "have rheumatoid arthritis (RA) in this guideline, which is a limitation but was beyond our scope, as questions regarding the timing of surgery in patients who have RA prioritize medication management to decrease infection risk, which was the focus of the updated 2022 ACR/AAHKS Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty This guideline has several strengths. The recommendations",
            "systemic inflammatory disease activity and are likely to be taking immunosuppressant medications at the time of surgery, the management of which was felt to be beyond the scope of this guideline. This was the focus of the 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty METHODS This",
            "guideline does not address arthroplasty for patients who have rheumatic diseases, as they were the focus of the recent ACR/AAHKS guideline for the perioperative management of antirheumatic medications in patients undergoing total hip and total knee arthroplasty A conditional recommendation means that the panel has inferred that the majority of informed patients would choose the recommended course of action, but that an appreciable minority would not. A shared decision-making process with full"
        ]
    },
    {
        "pregunta": "2. Why are all recommendations in the guideline considered conditional?",
        "respuesta": "The recommendations in the 2022 American College of Rheumatology guideline for the perioperative management of antirheumatic medication in patients undergoing elective total hip or total knee arthroplasty are considered conditional because the panel inferred that while the majority of informed patients would choose the recommended course of action, an appreciable minority might not. This acknowledges variability in patient preferences and highlights the importance of a shared decision-making process that incorporates individual patient circumstances and values.",
        "contexto": [
            "guideline does not address arthroplasty for patients who have rheumatic diseases, as they were the focus of the recent ACR/AAHKS guideline for the perioperative management of antirheumatic medications in patients undergoing total hip and total knee arthroplasty A conditional recommendation means that the panel has inferred that the majority of informed patients would choose the recommended course of action, but that an appreciable minority would not. A shared decision-making process with full",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty      32D6EF0B25CDA1FB80B29547C7367EA8 10.1002/acr.24893  This updated guideline addresses the perioperative management of disease modifying medications for adults with rheumatic diseases, specifically inflammatory arthritis (IA) and systemic lupus",
            "have rheumatoid arthritis (RA) in this guideline, which is a limitation but was beyond our scope, as questions regarding the timing of surgery in patients who have RA prioritize medication management to decrease infection risk, which was the focus of the updated 2022 ACR/AAHKS Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty This guideline has several strengths. The recommendations",
            "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty  American College of Rheumatology      D7E914B32636437769C151DE0A277789 10.1002/acr.24893 Submitted for publication February 9, 2022; accepted in revised form April 7, 2022.  INTRODUCTION Advances in antirheumatic therapy have led to remarkable",
            "systemic inflammatory disease activity and are likely to be taking immunosuppressant medications at the time of surgery, the management of which was felt to be beyond the scope of this guideline. This was the focus of the 2022 American College of Rheumatology (ACR)/American Association of Hip and Knee Surgeons (AAHKS) Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty METHODS This"
        ]
    },
    {
        "pregunta": "3. Which disease-modifying antirheumatic drugs (DMARDs) are conditionally recommended to be continued through surgery for patients with RA, AS, PsA, JIA, or SLE undergoing elective THA or TKA?",
        "respuesta": "According to the 2022 American College of Rheumatology guideline, the disease-modifying antirheumatic drugs (DMARDs) that are conditionally recommended to be continued through surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) who are undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA) are methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.",
        "contexto": [
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes",
            "<p>|Recommendation/strength of recommendation|Level of evidence|\n|---|---|\n|For patients with RA, AS, PsA, JIA, or all SLE undergoing THA or TKA, continuing the usual dosing of the following DMARDs through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast.†|Low to moderate|",
            "INTRODUCTION Advances in antirheumatic therapy have led to remarkable improvements in treatment and quality of life for people with rheumatic musculoskeletal diseases (RMDs); however, total hip arthroplasty (THA) and total knee arthroplasty (TKA) remain a mainstay of treatment among RMD patients with advanced symptomatic joint damage, most frequently those with inflammatory arthritis (IA), including spondylarthritis (SpA), rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with",
            "diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,"
        ]
    },
    {
        "pregunta": "4. What is the recommendation for withholding biologics, including rituximab, prior to surgery for patients with RA, AS, PsA, or JIA undergoing elective THA or TKA?",
        "respuesta": "The 2022 American College of Rheumatology guideline conditionally recommends withholding all biologics, including rituximab, prior to surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or juvenile idiopathic arthritis (JIA) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA). The surgery should be planned after the next dose of the biologic is due. This recommendation is based on indirect evidence and a lack of a comparator group in the included studies.",
        "contexto": [
            "AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients",
            "|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|",
            "and/or apremilast. This conditional recommendation now includes apremilast, but it is otherwise unchanged from the 2017 guideline. Four observational studies provided additional indirect evidence to the previous systematic literature review and found no relationship between the included drugs and the risk of postoperative infections, although the number of included cases and events were low For patients with RA, AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics,",
            "management of DMARDs, biologics, and GCs for adult patients with RA, SpA including AS and PsA, JIA, and SLE undergoing elective THA or TKA. This guideline is intended for use by clinicians and patients and balances the risk of flares of disease when medications are withheld versus infection risk attributed to the medications when they are continued. This update adds new medications introduced and reviews the studies published since the 2017 ACR/AAHKS guideline that have informed our",
            "have rheumatoid arthritis (RA) in this guideline, which is a limitation but was beyond our scope, as questions regarding the timing of surgery in patients who have RA prioritize medication management to decrease infection risk, which was the focus of the updated 2022 ACR/AAHKS Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty This guideline has several strengths. The recommendations"
        ]
    },
    {
        "pregunta": "5. How should glucocorticoid therapy be managed for patients with RA, AS, PsA, or SLE undergoing THA or TKA?",
        "respuesta": "The recommendations for managing glucocorticoid therapy in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) are to continue their current daily dose of glucocorticoids rather than administering supraphysiologic doses on the day of surgery. This is a conditional recommendation based on low-quality evidence.",
        "contexto": [
            "|For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended.|Low|</p>",
            "rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative medication management remains unknown, but antirheumatic therapy is a readily modifiable risk factor for infection, whereas other risk factors for adverse outcomes, including disease activity or severity or longterm glucocorticoid (GC) use, may not be modifiable Given the increased infection risk seen in patients with IA and patients with SLE",
            "management of DMARDs, biologics, and GCs for adult patients with RA, SpA including AS and PsA, JIA, and SLE undergoing elective THA or TKA. This guideline is intended for use by clinicians and patients and balances the risk of flares of disease when medications are withheld versus infection risk attributed to the medications when they are continued. This update adds new medications introduced and reviews the studies published since the 2017 ACR/AAHKS guideline that have informed our",
            "<h1>Recommendation pertains to infection risk and does not account for risk of cardiac events or venous thromboembolism.</h1>\n\n<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes"
        ]
    },
    {
        "pregunta": "6. What is the updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with RA, AS, PsA, or JIA undergoing THA or TKA?",
        "respuesta": "The updated recommendation for withholding tofacitinib, baricitinib, and upadacitinib prior to surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or juvenile idiopathic arthritis (JIA) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) is to withhold these medications for at least 3 days prior to surgery. This is a conditional recommendation based on low-quality evidence.",
        "contexto": [
            "|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended.|Low|\n|For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended.‡|Low|",
            "(see Table 2 For patients with RA, AS, PsA, or JIA undergoing THA or TKA, withholding tofacitinib, baricitinib, and upadacitinib for at least 3 days prior to surgery is conditionally recommended. This conditional recommendation was changed from the prior guideline. For the previous guideline, while the short serum half-life of tofacitinib was known, concern for a longer duration of the immune effect prompted the recommendation to withhold tofacitinib for 7 days prior to surgery. The new",
            "AS, PsA, or JIA undergoing elective THA or TKA, withholding all biologics, including rituximab, prior to surgery and planning the surgery after the next dose is due is conditionally recommended. This recommendation no longer includes patients with SLE, who are addressed separately (see below for rationale) but has not otherwise changed. Table 2 This recommendation is conditional because the evidence is indirect and there is a lack of a comparator group in the included studies Low For patients",
            "to withhold tofacitinib for 7 days prior to surgery. The new recommendation was informed by trial data demonstrating rapid increases in disease activity after interrupting tofacitinib therapy, suggesting a rapid reversal of the immunosuppressive effects, so the recommendation was changed to withhold tofacitinib for 3 days prior to surgery For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine,",
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes"
        ]
    },
    {
        "pregunta": "7. What medications are conditionally recommended to be withheld for patients with SLE (not severe) undergoing THA or TKA?",
        "respuesta": "For patients with non-severe systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA), the medications conditionally recommended to be withheld are:\n\n1. Mycophenolate mofetil\n2. Mycophenolic acid\n3. Azathioprine\n4. Cyclosporine\n5. Mizoribine\n6. Tacrolimus\n\nThese should be withheld 1 week prior to surgery. Additionally, it is conditionally recommended to withhold the usual dose of:\n\n1. Belimumab\n2. Rituximab\n\nPrior to surgery.",
        "contexto": [
            "|For patients with SLE (not severe) undergoing THA or TKA, withholding the current dose of mycophenolate mofetil, mycophenolic acid, azathioprine, cyclosporine, mizoribine, or tacrolimus 1 week prior to surgery is conditionally recommended.|Low|\n|For patients with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended.|Low|",
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,",
            "<h1>Recommendation pertains to infection risk and does not account for risk of cardiac events or venous thromboembolism.</h1>\n\n<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "diseases, specifically inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) and total knee arthroplasty (TKA). A panel of rheumatologists, orthopaedic surgeons, and infectious disease specialists updated the systematic literature review and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions, updating the 2017 recommendations*. As patients with IA"
        ]
    },
    {
        "pregunta": "8. What is the recommendation for patients with severe SLE undergoing THA or TKA regarding the continuation of belimumab and rituximab?",
        "respuesta": "For patients with severe systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA), it is conditionally recommended to continue belimumab and to plan the surgery in the last month of the dosing cycle for rituximab. This recommendation is based on low-quality evidence and takes into account the use of belimumab in severe SLE, including nephritis, along with its low infection risk as described in clinical trials.",
        "contexto": [
            "As noted in the previous guideline, the patient's rheumatologist should be consulted regarding medication management. A patient with severe SLE who has been stable for >6 months or who has a history of recurrent or severe infections might discontinue the medications in the perioperative period. For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended. In the prior guideline,",
            "with SLE (not severe) undergoing THA or TKA, withholding the usual dose of belimumab and rituximab prior to surgery is conditionally recommended. This recommendation is unchanged from the prior guideline. Patients with SLE that is not severe would not be at risk for permanent organ damage should they flare. In addition, nonsevere SLE patients could be followed up closely after surgery, and an intervention could be made to treat a flare as needed. Patients with frequent flares or SLE that is",
            "|For patients with severe SLE who have been deemed appropriate to undergo THA or TKA, continuing the usual dose of mycophenolate mofetil, mycophenolic acid (Myfortic), azathioprine, mizoribine, cyclosporine, or tacrolimus, anifrolumab, and voclosporin through surgery is conditionally recommended.‡|Low|\n|For patients with severe SLE undergoing THA or TKA, continuing belimumab and planning surgery in the last month of the dosing cycle of rituximab is conditionally recommended.‡|Low|",
            "for the use of belimumab in severe SLE including nephritis, as well as increased comfort with belimumab among clinicians and patients given its widespread use, low infection risk described in clinical trials, and inclusion in SLE treatment guidelines For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/ staples are out,",
            "<h1>Recommendation pertains to infection risk and does not account for risk of cardiac events or venous thromboembolism.</h1>\n\n<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>"
        ]
    },
    {
        "pregunta": "9. When should antirheumatic therapy be restarted for patients with RA, AS, PsA, or SLE who underwent total joint arthroplasty?",
        "respuesta": "For patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) who have undergone total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures or staples are out, there is no significant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection. This typically occurs around 14 days post-surgery.",
        "contexto": [
            "<p>§ Drug added for 2022 update.</p>\n\n<p>¶ For patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/staples are out, there is no signiﬁcant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which is typically ~14 days.</p>",
            "for the use of belimumab in severe SLE including nephritis, as well as increased comfort with belimumab among clinicians and patients given its widespread use, low infection risk described in clinical trials, and inclusion in SLE treatment guidelines For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing total joint arthroplasty, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/ staples are out,",
            "|For patients with RA, AS, PsA, or all SLE for whom antirheumatic therapy was withheld prior to undergoing TJA, antirheumatic therapy should be restarted once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling, erythema, or drainage, and there is no ongoing nonsurgical site infection, which is typically ~14 days, is conditionally recommended.|Low|",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,",
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes"
        ]
    },
    {
        "pregunta": "10. What is the recommendation for managing glucocorticoid therapy on the day of surgery for patients with RA, AS, PsA, or SLE undergoing THA or TKA?",
        "respuesta": "The recommendation for managing glucocorticoid therapy on the day of surgery for patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) is to continue their current daily dose of glucocorticoids rather than administering supraphysiologic doses. This is a conditional recommendation based on low-quality evidence.",
        "contexto": [
            "|For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended.|Low|</p>",
            "is a lack of a comparator group in the included studies Low For patients with RA, AS, PsA, or all SLE undergoing THA or TKA who are receiving glucocorticoids for their rheumatic condition, continuing their current daily dose of glucocorticoids rather than administering supraphysiologic doses of glucocorticoids on the day of surgery is conditionally recommended. surgery, although patients receiving intravenous abatacept within 2 weeks of surgery (one-half of a dosing interval) had a numerically",
            "rheumatoid arthritis (RA), or psoriatic arthritis (PsA), and those with systemic lupus erythematosus (SLE) The optimal strategy for perioperative medication management remains unknown, but antirheumatic therapy is a readily modifiable risk factor for infection, whereas other risk factors for adverse outcomes, including disease activity or severity or longterm glucocorticoid (GC) use, may not be modifiable Given the increased infection risk seen in patients with IA and patients with SLE",
            "includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease modifying medication management for patients with IA and SLE at the time of elective THA or TKA. ***For patients with RA, AS, PsA, or all SLE for whom anti-rheumatic therapy was held prior to undergoing TJA, restarting the anti-rheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling,",
            "to August 26, 2021) are not included in these recommendations. 4. PICO questions were combined in the final recommendations for clarity. Recommendations For patients with RA, AS, PsA, JIA, or all SLE undergoing elective THA or TKA, continuing the usual dosing of the following disease-modifying antirheumatic drugs (DMARDs) through surgery is conditionally recommended: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and/or apremilast. This conditional recommendation now includes"
        ]
    }
]